UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Brussels (Belgium), January 15, 2025 – 7:00 CET –UCB (Euronext: UCB), a global biopharmaceutical leader dedicated to transforming the lives of people living with severe diseases, presents today its growth journey and the strategic priorities driving its success into the future at the 43rd J.P. Morgan Healthcare Conference in San Francisco, U.S. Over the past decade, UCB has focused on developing solutions in immunology and neurology, driven by its patient value strategy. Going ahead, UCB expects a decade-plus of growth.

Delivering on Ambitions    

With nearly 100 years of excellence in biopharmaceuticals, UCB has built a legacy of patient-centered innovation. The company’s Patient Value Strategy has driven the development of transformative medicines, enabling a decade plus of growth and setting the stage for continued success.

“At UCB, we are looking ahead with confidence and determination. We will continue to deliver differentiated innovation, transforming what is possible for patients, caregivers, medical professionals and shareholders. Guided by our Patient Value Strategy, we are committed to delivering solutions that truly make a difference, while ensuring a sustainable and inclusive future for all,” said Jean-Christophe Tellier, CEO of UCB. 

Key highlights from the presentation    

• BIMZELX^® (bimekizumab) now has significantly improved insurance coverage in the U.S., making it easier for patients to access and afford. BIMZELX^® is available to patients in 48 countries.
• RYSTIGGO^® (rozanolixizumab) and ZILBRYSQ^® (zilucoplan): UCB is the first and only company with a differentiated gMG portfolio and market authorization in more than 20 countries. 
• R&D Leadership: Industry-leading productivity has resulted in multiple positive Phase 3 results, 25 approvals and launches across major regions, including the U.S., EU, and Japan, in the last 24 months.
• Sustainability Excellence: UCB is one of only few biopharma companies with validated net-zero targets by the Science Based Targets initiative (SBTi), which underscores its commitment to environmental and societal well-being.
• Financial Growth: As per guidance update in November 2024 and for 2024, UCB is expecting revenue near €6 billion and an adjusted EBITDA margin within the upper part of the range of 23.0-24.5%. Full year 2024 financial results will be announced on February 27, 2025.

Confidence in a future of sustained growth    

UCB aims to continue its growth by focusing on innovative medicines that make a real difference for patients, caregivers, and medical professionals. The company is dedicated to creating a sustainable and inclusive future for all.

The CEO's presentation and webcast at the J.P. Morgan conference will be available this evening on the UCB website in the Investor Relations section. 

For further information, contact UCB: 

Investor Relations
Antje Witte
T: +32.2.559.94.14 
Email: antje.witte@ucb.com 

Sahar Yazdian
T: +32 2 559 9137
sahar.yazdian@ucb.com 

Corporate Communications
Laurent Schots 
T: +32.2.559.92.64 
Email:  laurent.schots@ucb.com

About UCB 
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9 000 people in approximately 40 countries, the company generated revenue of € 5.3 billion in 2023. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on X: @UCB_news

Forward looking statements 
This press release contains forward-looking statements, including, without limitation, statements containing the words “potential”, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this press release.  
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’s efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems. 
Given these uncertainties, you are cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this press release, and do not reflect any potential impacts from the evolving conflicts, wars, pandemics, as well as any other adversity, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB. 
UCB expressly disclaims any obligation or duty to update any forward-looking statements in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.